Yağmur Kiraz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yağmur Kiraz has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Başak Özay
İzmir University of Economics
2 shared publications - Beste Turanli
Department of Bioengineering, Faculty of Engineering, Marmara University, Istanbul 34854, Turkey
2 shared publications - Ezgi Yağmur Tükel
Department of Genetics and Bioengineering, Faculty of Engineering, Izmir University of Economics, Balçova, Türkiye
2 shared publications - Gizem Ayna Duran
Izmir Ekonomi Universitesi
2 shared publications - Onur Ates
İzmir University of Economics
2 shared publications Onur Ateş
Faculty of Engineering, Department of Genetics and Bioengineering, İzmir University of Economics, Balçova, İzmir
2 shared publications
Latest Publications
- Open Access
- 25 April 2026
- Published by Springer Nature in Medical Oncology
- Vol. 43 (6) , 184
Targeting STAT5A via CRISPR/Cas9 restores TKI sensitivity in resistant chronic myeloid leukemia cells
Therapeutic resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge in the clinical management of chronic myeloid leukemia (CML). The transcription factor STAT5A, a principal downstream effector of BCR::ABL1, has emerged as a key transcriptional regulator implicated in the development of TKI resistance. This study aims to functionally validate the role of STAT5A in TKI-resistant CML by employing CRISPR/Cas9-mediated gene knockout and assessing the downstream molecular and phenotypic alterations. We hypothesized that selective disruption of STAT5A would restore apoptotic sensitivity and TKI responsiveness in resistant CML models. Additionally, we sought to integrate bioinformatic transcriptional network analyses to confirm whether STAT5A directly regulates the genes modulated by its deletion, thus reinforcing its mechanistic relevance as a therapeutic target. STAT5A was knocked out using CRISPR/Cas9 in K562 cells and their TKI-resistant derivatives (K562/Ima-Res, K562/Pon-Res). Western blot analysis confirmed effective depletion of STAT5A protein following CRISPR/Cas9 editing, validating that the observed phenotypic and transcriptional changes were attributable to successful STAT5A knockout. Post-editing, XTT assays were performed to assess cell viability, followed by Annexin V/PI staining for apoptosis and PI-based flow cytometry for cell cycle analysis. RT-qPCR was used to quantify the expression of key genes involved in the JAK/STAT pathway (JAK2, STAT3, CISH) and apoptosis/DNA damage responses (TP53, ATM, CASP3, CASP8). In silico analyses were conducted using TRRUST and Harmonizome/ChEA3 to confirm whether the genes modulated by STAT5A deletion were direct transcriptional targets. For additional validation, expression matrices from GSE207627 and GSE208314 were reanalyzed to confirm STAT5A-centered pathway alterations in resistant CML datasets. STAT5A knockout significantly reduced cell viability and induced apoptosis across all CML cell models, accompanied by G0/G1 cell cycle arrest. RT-qPCR revealed altered expression of both JAK/STAT components (JAK2, STAT3, CISH) and apoptosis-related genes (TP53, ATM, CASP3, CASP8). Transcriptional target analysis confirmed that several of these genes—such as CDKN2B, BCL2L1, and CCND1—are direct STAT5A targets, reinforcing the functional consequences of STAT5A loss. Integration of these findings suggests that STAT5A knockout reprograms both intrinsic (CASP3, TP53, ATM) and extrinsic (CASP8, BCL2L1) apoptotic pathways, thereby restoring chemosensitivity. CISH dysregulation further suggested compensatory feedback within the signaling network. CRISPR/Cas9-mediated STAT5A disruption effectively reverses TKI resistance in CML cells by reprogramming apoptotic and proliferative signaling. These findings identify STAT5A as a mechanistically validated and clinically actionable target, supporting its potential for combination strategies with TKIs or STAT5 inhibitors such as pimozide. Integration of transcriptional network analysis supports the mechanistic basis of these effects. STAT5A emerges as a compelling therapeutic target, meriting further investigation in preclinical models and patient-derived samples to evaluate its translational potential. Future validation in patient-derived CD34⁺ CML models may advance STAT5A-based therapeutic design.
- 25 April 2026
- Published by Springer Nature in Medical Oncology
- Vol. 43 (6) , 184
Open AccessTargeting STAT5A via CRISPR/Cas9 restores TKI sensitivity in resistant chronic myeloid leukemia cells
Therapeutic resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge in the clinical management of chronic myeloid leukemia (CML). The transcription factor STAT5A, a principal downstream effector of BCR::ABL1, has emerged as a key transcriptional regulator implicated in the development of TKI resistance. This study aims to functionally validate the role of STAT5A in TKI-resistant CML by employing CRISPR/Cas9-mediated gene knockout and assessing the downstream molecular and phenotypic alterations. We hypothesized that selective disruption of STAT5A would restore apoptotic sensitivity and TKI responsiveness in resistant CML models. Additionally, we sought to integrate bioinformatic transcriptional network analyses to confirm whether STAT5A directly regulates the genes modulated by its deletion, thus reinforcing its mechanistic relevance as a therapeutic target. STAT5A was knocked out using CRISPR/Cas9 in K562 cells and their TKI-resistant derivatives (K562/Ima-Res, K562/Pon-Res). Western blot analysis confirmed effective depletion of STAT5A protein following CRISPR/Cas9 editing, validating that the observed phenotypic and transcriptional changes were attributable to successful STAT5A knockout. Post-editing, XTT assays were performed to assess cell viability, followed by Annexin V/PI staining for apoptosis and PI-based flow cytometry for cell cycle analysis. RT-qPCR was used to quantify the expression of key genes involved in the JAK/STAT pathway (JAK2, STAT3, CISH) and apoptosis/DNA damage responses (TP53, ATM, CASP3, CASP8). In silico analyses were conducted using TRRUST and Harmonizome/ChEA3 to confirm whether the genes modulated by STAT5A deletion were direct transcriptional targets. For additional validation, expression matrices from GSE207627 and GSE208314 were reanalyzed to confirm STAT5A-centered pathway alterations in resistant CML datasets. STAT5A knockout significantly reduced cell viability and induced apoptosis across all CML cell models, accompanied by G0/G1 cell cycle arrest. RT-qPCR revealed altered expression of both JAK/STAT components (JAK2, STAT3, CISH) and apoptosis-related genes (TP53, ATM, CASP3, CASP8). Transcriptional target analysis confirmed that several of these genes—such as CDKN2B, BCL2L1, and CCND1—are direct STAT5A targets, reinforcing the functional consequences of STAT5A loss. Integration of these findings suggests that STAT5A knockout reprograms both intrinsic (CASP3, TP53, ATM) and extrinsic (CASP8, BCL2L1) apoptotic pathways, thereby restoring chemosensitivity. CISH dysregulation further suggested compensatory feedback within the signaling network. CRISPR/Cas9-mediated STAT5A disruption effectively reverses TKI resistance in CML cells by reprogramming apoptotic and proliferative signaling. These findings identify STAT5A as a mechanistically validated and clinically actionable target, supporting its potential for combination strategies with TKIs or STAT5 inhibitors such as pimozide. Integration of transcriptional network analysis supports the mechanistic basis of these effects. STAT5A emerges as a compelling therapeutic target, meriting further investigation in preclinical models and patient-derived samples to evaluate its translational potential. Future validation in patient-derived CD34⁺ CML models may advance STAT5A-based therapeutic design.
- Open Access
- 4 February 2026
- Published by PAGEPress Publications in Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale
Unraveling bortezomib resistance in multiple myeloma: insights from RNA-Seq and PI3K/mTOR pathway analysis
Multiple Myeloma (MM), characterized by abnormal plasma cell proliferation, lacks curative treatment due to drug resistance, notably against Bortezomib, a critical proteasome inhibitor. To elucidate resistance mechanisms, we conducted RNA sequencing on Bortezomib-sensitive and resistant RPMI-8226 MM cells, comparing them to healthy B-cells. Differential expression analysis highlighted significant alterations in immune signaling, proteasome function, and metabolism. Resistant MM cells exhibited decreased antigen-presentation genes (HLA-DRA, HLA-DPA1, CD74), indicating immune evasion. Downregulation of metabolic regulators like GLUL and MDK suggested a glycolytic metabolic shift, whereas enhanced proteasome activities and nucleocytoplasmic transport represented adaptive strategies against proteotoxic stress. Importantly, resistant cells showed notable upregulation of PRAME and FAF1 genes, as oncogenes and apoptosis-related genes linked to therapy resistance. Pathway analysis revealed enrichment in neurodegenerative disease-related pathways, suggesting common protein misfolding mechanisms in MM progression. Additionally, resistant cells displayed cross-resistance to the dual protein kinase B (AKT)/mammalian target of rapamycin (mTOR) BEZ235, with a four-fold increase in IC₅₀ values, reflecting enhanced survival signaling and metabolic flexibility. These findings underscore the multifaceted nature of Bortezomib resistance, driven by metabolic reprogramming, immune modulation, and translational regulation. Targeting these adaptive pathways through combination therapies involving proteasome inhibitors, metabolic modulators, and autophagy inhibitors may present novel strategies to overcome drug resistance in MM.
- 4 February 2026
- Published by PAGEPress Publications in Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale
Open AccessUnraveling bortezomib resistance in multiple myeloma: insights from RNA-Seq and PI3K/mTOR pathway analysis
Multiple Myeloma (MM), characterized by abnormal plasma cell proliferation, lacks curative treatment due to drug resistance, notably against Bortezomib, a critical proteasome inhibitor. To elucidate resistance mechanisms, we conducted RNA sequencing on Bortezomib-sensitive and resistant RPMI-8226 MM cells, comparing them to healthy B-cells. Differential expression analysis highlighted significant alterations in immune signaling, proteasome function, and metabolism. Resistant MM cells exhibited decreased antigen-presentation genes (HLA-DRA, HLA-DPA1, CD74), indicating immune evasion. Downregulation of metabolic regulators like GLUL and MDK suggested a glycolytic metabolic shift, whereas enhanced proteasome activities and nucleocytoplasmic transport represented adaptive strategies against proteotoxic stress. Importantly, resistant cells showed notable upregulation of PRAME and FAF1 genes, as oncogenes and apoptosis-related genes linked to therapy resistance. Pathway analysis revealed enrichment in neurodegenerative disease-related pathways, suggesting common protein misfolding mechanisms in MM progression. Additionally, resistant cells displayed cross-resistance to the dual protein kinase B (AKT)/mammalian target of rapamycin (mTOR) BEZ235, with a four-fold increase in IC₅₀ values, reflecting enhanced survival signaling and metabolic flexibility. These findings underscore the multifaceted nature of Bortezomib resistance, driven by metabolic reprogramming, immune modulation, and translational regulation. Targeting these adaptive pathways through combination therapies involving proteasome inhibitors, metabolic modulators, and autophagy inhibitors may present novel strategies to overcome drug resistance in MM.
- Open Access
- 1 January 2026
- Published by Walter de Gruyter GmbH in Open Chemistry
- Vol. 24 (1)
Toxicity assessment of phthalates and binary mixtures on differentiated three-dimensional pancreatic cell model
Currently, the development of new in vitro models and the enhancement of existing ones are increasingly prioritized to significantly reduce laboratory animal use, in line with the 3R principles (replacement, reduction, and refinement) of animal welfare legislation. This study aims to evaluate the cytotoxic effects of individual and binary mixtures of selected phthalates on differentiated pancreatic cell models-islet-like cell aggregates (ICA), developed from human pancreatic carcinoma (PANC-1) cells. In this study, PANC-1 cells are differentiated into ICA which was confirmed by microscopy imaging and the determining the levels of insulin, glucagon, somatostatin and stem cell factor (cKIT) by ELISA assay. Expression levels of NGN3, ISL-1, INS, GCG, PDX and SST marker genes were evaluated by RT-qPCR. Differentiated cells are exposed to diethyl phthalate (DEP), dimethyl phthalate (DMP), dibutyl phthalate (DBP) and diisobutyl phthalate (DiBP). IC50 values were calculated as 870.215, 571.390, 589.219 and 388.471 µM, respectively, for DEP, DMP, DBP and DiBP. All binary mixtures displayed antagonism starting from IC10 values, except, DMP + DBP mixture displayed synergism at the IC90 level.
- 1 January 2026
- Published by Walter de Gruyter GmbH in Open Chemistry
- Vol. 24 (1)
Open AccessToxicity assessment of phthalates and binary mixtures on differentiated three-dimensional pancreatic cell model
Currently, the development of new in vitro models and the enhancement of existing ones are increasingly prioritized to significantly reduce laboratory animal use, in line with the 3R principles (replacement, reduction, and refinement) of animal welfare legislation. This study aims to evaluate the cytotoxic effects of individual and binary mixtures of selected phthalates on differentiated pancreatic cell models-islet-like cell aggregates (ICA), developed from human pancreatic carcinoma (PANC-1) cells. In this study, PANC-1 cells are differentiated into ICA which was confirmed by microscopy imaging and the determining the levels of insulin, glucagon, somatostatin and stem cell factor (cKIT) by ELISA assay. Expression levels of NGN3, ISL-1, INS, GCG, PDX and SST marker genes were evaluated by RT-qPCR. Differentiated cells are exposed to diethyl phthalate (DEP), dimethyl phthalate (DMP), dibutyl phthalate (DBP) and diisobutyl phthalate (DiBP). IC50 values were calculated as 870.215, 571.390, 589.219 and 388.471 µM, respectively, for DEP, DMP, DBP and DiBP. All binary mixtures displayed antagonism starting from IC10 values, except, DMP + DBP mixture displayed synergism at the IC90 level.
- 2 November 2025
- Published by Taylor & Francis in Personalized Medicine
- Vol. 22 (6) , 421-435
Lineage-specific transcriptomic signatures and therapeutic target discovery in myeloid and lymphoid leukemias
Leukemias are heterogenous hematologic malignancies broadly classified into myeloid and lymphoid lineages, each with distinct molecular and clinical features. Here we aime to identify lineage-specific molecular vulnerabilities in myeloid and lymphoid leukemias and use them to guide targeted therapy and rational drug repurposing. A meta-analysis of 19 GEO datasets comprising >2,600 samples from acute and chronic leukemia subtypes was performed. Differentially expressed genes (DEGs) were identified and subjected to functional enrichment and protein-protein interaction (PPI) network analyses. Hub genes were identified for drug repurposing using the LINCS L1000CDS2. Candidate compounds were validated by performing molecular docking, dynamics simulations and MTT assays on multiple leukemia cell lines. 269 DEGs in myeloid and 316 DEGs in lymphoid leukemias were identified. Enrichment analysis showed that DNA replication and cell cycle pathways drive myeloid leukemias, while lymphoid leukemias are associated with transcriptional regulation and immune signaling. Hub genes included CCNB1, KIF11, EGFR and JUN. SN-38 and C646 were identified as promising candidates from drug repurposing. Docking and molecular dynamics simulations confirmed strong binding to IGF1R and RBP2. MTT assays revealed significant, time- and dose-dependent cytotoxicity. This integrative approach links transcriptomics with drug discovery and preclinical validation. Lineage-specific vulnerabilities were uncovered, providing a framework for precision therapy and rational drug repurposing in leukemia.
- 2 November 2025
- Published by Taylor & Francis in Personalized Medicine
- Vol. 22 (6) , 421-435
Lineage-specific transcriptomic signatures and therapeutic target discovery in myeloid and lymphoid leukemias
Leukemias are heterogenous hematologic malignancies broadly classified into myeloid and lymphoid lineages, each with distinct molecular and clinical features. Here we aime to identify lineage-specific molecular vulnerabilities in myeloid and lymphoid leukemias and use them to guide targeted therapy and rational drug repurposing. A meta-analysis of 19 GEO datasets comprising >2,600 samples from acute and chronic leukemia subtypes was performed. Differentially expressed genes (DEGs) were identified and subjected to functional enrichment and protein-protein interaction (PPI) network analyses. Hub genes were identified for drug repurposing using the LINCS L1000CDS2. Candidate compounds were validated by performing molecular docking, dynamics simulations and MTT assays on multiple leukemia cell lines. 269 DEGs in myeloid and 316 DEGs in lymphoid leukemias were identified. Enrichment analysis showed that DNA replication and cell cycle pathways drive myeloid leukemias, while lymphoid leukemias are associated with transcriptional regulation and immune signaling. Hub genes included CCNB1, KIF11, EGFR and JUN. SN-38 and C646 were identified as promising candidates from drug repurposing. Docking and molecular dynamics simulations confirmed strong binding to IGF1R and RBP2. MTT assays revealed significant, time- and dose-dependent cytotoxicity. This integrative approach links transcriptomics with drug discovery and preclinical validation. Lineage-specific vulnerabilities were uncovered, providing a framework for precision therapy and rational drug repurposing in leukemia.
- 5 July 2025
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 38 (5) , 1-17
Determination of survival associated genetic biomarkers to discover novel therapeutic targets for acute myeloid leukaemia
Acute myeloid leukemia (AML) is a heterogeneous malignancy specified by clonal proliferation of hematopoietic stem cells. This study identifies novel therapeutics for AML by integrating differential gene expression (DEG) and survival analyses. Publicly available GEO microarray datasets were analyzed, including data from 615 AML patients and 22 healthy controls. Multivariate Cox regression identified hazardous genes impacting survival. Protein-protein interaction networks using CytoScape revealed hub genes such as CCT5, ZBTB16, APP, and PTPN6. Functional enrichment revealed key AML-related pathways, such as PI3K/Akt and NF-kappaB signaling. Drug repurposing using the LINCS L1000CDS2 database highlighted potential therapeutics, including 16-Hydroxytriptolide and Tryptosthin AG-1478, with roles in reversing hazardous gene expression patterns. Additional candidates such as Vemurafenib, Parthenolide and Wortmannin, demonstrated promise as targeted agents. These findings underscore the potential of integrating bioinformatics and drug discovery to identify precision medicine in AML. Further studies are warranted to validate these targets and explore their clinical utility.
- 5 July 2025
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 38 (5) , 1-17
Determination of survival associated genetic biomarkers to discover novel therapeutic targets for acute myeloid leukaemia
Acute myeloid leukemia (AML) is a heterogeneous malignancy specified by clonal proliferation of hematopoietic stem cells. This study identifies novel therapeutics for AML by integrating differential gene expression (DEG) and survival analyses. Publicly available GEO microarray datasets were analyzed, including data from 615 AML patients and 22 healthy controls. Multivariate Cox regression identified hazardous genes impacting survival. Protein-protein interaction networks using CytoScape revealed hub genes such as CCT5, ZBTB16, APP, and PTPN6. Functional enrichment revealed key AML-related pathways, such as PI3K/Akt and NF-kappaB signaling. Drug repurposing using the LINCS L1000CDS2 database highlighted potential therapeutics, including 16-Hydroxytriptolide and Tryptosthin AG-1478, with roles in reversing hazardous gene expression patterns. Additional candidates such as Vemurafenib, Parthenolide and Wortmannin, demonstrated promise as targeted agents. These findings underscore the potential of integrating bioinformatics and drug discovery to identify precision medicine in AML. Further studies are warranted to validate these targets and explore their clinical utility.
- Open Access
- 25 March 2025
- Published by Marmara University in International Journal of Advances in Engineering and Pure Sciences
- Vol. 37 (1) , 64-72
PSMB8 as a Novel Target for AML Therapy: Uncovering Synergistic Potential with PI3K Inhibitors
Acute myeloid leukemia (AML) is a bone marrow condition that arises from abnormalities in hematopoietic stem cells due to genetic mutations in progenitor blood cells. These mutations lead to the uncontrolled proliferation of malignant clonal myeloid stem cells. Although extramedullary symptoms such as myeloid sarcomas and leukemia cutis can arise, the main issue continues to be the disturbances in hematologic cell production. Despite the high complete remission rate in elderly patients, a notable number of patients experience relapse within three years. To address this issue, new objectives must be identified. In a previous study, PSMB8 drew our attention due to its elevated expression levels in AML patients exhibiting lower survival rates compared to those with reduced expression levels. PSMB8 was used for drug repurposing studies by performing in silico drug screening, an ADMET analysis which is followed by Molecular Dynamics (MD) simulations. Three ligand molecules were identified as potential treatment options for AML which were Adozelesin, Fiduxosin and Omipalisib. Omipalisib is known as a PI3K/mTOR inhibitor which was taken our attention for cytotoxic analysis due to overexpression of PI3K/mTOR pathway proteins in AML development. In the subsequent phase, we assessed the cytotoxicity of Omipalisib in comparison to ONX-0914, an inhibitor of PSMB8, in the HL60 cell lines. This research indicated that PSMB8 could be a possible target for Acute Myeloid Leukemia and that a potential medication can be utilized for targeted treatment.
- 25 March 2025
- Published by Marmara University in International Journal of Advances in Engineering and Pure Sciences
- Vol. 37 (1) , 64-72
Open AccessPSMB8 as a Novel Target for AML Therapy: Uncovering Synergistic Potential with PI3K Inhibitors
Acute myeloid leukemia (AML) is a bone marrow condition that arises from abnormalities in hematopoietic stem cells due to genetic mutations in progenitor blood cells. These mutations lead to the uncontrolled proliferation of malignant clonal myeloid stem cells. Although extramedullary symptoms such as myeloid sarcomas and leukemia cutis can arise, the main issue continues to be the disturbances in hematologic cell production. Despite the high complete remission rate in elderly patients, a notable number of patients experience relapse within three years. To address this issue, new objectives must be identified. In a previous study, PSMB8 drew our attention due to its elevated expression levels in AML patients exhibiting lower survival rates compared to those with reduced expression levels. PSMB8 was used for drug repurposing studies by performing in silico drug screening, an ADMET analysis which is followed by Molecular Dynamics (MD) simulations. Three ligand molecules were identified as potential treatment options for AML which were Adozelesin, Fiduxosin and Omipalisib. Omipalisib is known as a PI3K/mTOR inhibitor which was taken our attention for cytotoxic analysis due to overexpression of PI3K/mTOR pathway proteins in AML development. In the subsequent phase, we assessed the cytotoxicity of Omipalisib in comparison to ONX-0914, an inhibitor of PSMB8, in the HL60 cell lines. This research indicated that PSMB8 could be a possible target for Acute Myeloid Leukemia and that a potential medication can be utilized for targeted treatment.
- Open Access
- 11 July 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (9) , 3835
Correction to: Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities
- 11 July 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (9) , 3835
Open AccessCorrection to: Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities
- 2 July 2024
- Published by Springer Nature in Molecular Biotechnology
- Vol. 67 (7) , 2617-2627
In Silico Drug Repurposing Against PSMB8 as a Potential Target for Acute Myeloid Leukemia Treatment
PSMB8 emerges as a prominent gene associated with cancer survival, yet its potential therapeutic role in acute myeloid leukemia (AML) remains unexplored within the existing literature. The principal aim of this study is to systematically screen an expansive library of molecular entities, curated from various databases to identify the prospective inhibitory agents with an affinity for PSMB8. A comprehensive assortment of molecular compounds obtained from the ZINC15 database was subjected to molecular docking simulations with PSMB8 by using the AutoDock tool in PyRx (version 0.9.9) to elucidate binding affinities. Following the docking simulations, a select subset of molecules underwent further investigation through comprehensive ADMET (absorption, distribution, metabolism, excretion, and toxicity) analysis employing AdmetSar and SwissADME tools. Finally, RMSD, RMSF, Rg, and H bond analyses were conducted via GROMACS to determine the best conformationally dynamic molecule that represents the candidate agent for the study. Following rigorous evaluation, Adozelesin, Fiduxosin, and Rimegepant have been singled out based on considerations encompassing bioavailability scores, compliance with filter criteria, and acute oral toxicity levels. Additionally, ligand interaction analysis indicates that Adozelesin and Fiduxosin exhibit an augmented propensity for hydrogen bond formation, a factor recognized for its facilitative role in protein–ligand interactions. After final analyses, we report that Fiduxosin may offer a treatment possibility by reversing the low survival rates caused by PSMB8 high activation in AML. This study represents a strategic attempt to repurpose readily available pharmaceutical agents, potentially obviating the need for de novo drug development, and thereby offering promising avenues for therapeutic intervention in specific diseases.
- 2 July 2024
- Published by Springer Nature in Molecular Biotechnology
- Vol. 67 (7) , 2617-2627
In Silico Drug Repurposing Against PSMB8 as a Potential Target for Acute Myeloid Leukemia Treatment
PSMB8 emerges as a prominent gene associated with cancer survival, yet its potential therapeutic role in acute myeloid leukemia (AML) remains unexplored within the existing literature. The principal aim of this study is to systematically screen an expansive library of molecular entities, curated from various databases to identify the prospective inhibitory agents with an affinity for PSMB8. A comprehensive assortment of molecular compounds obtained from the ZINC15 database was subjected to molecular docking simulations with PSMB8 by using the AutoDock tool in PyRx (version 0.9.9) to elucidate binding affinities. Following the docking simulations, a select subset of molecules underwent further investigation through comprehensive ADMET (absorption, distribution, metabolism, excretion, and toxicity) analysis employing AdmetSar and SwissADME tools. Finally, RMSD, RMSF, Rg, and H bond analyses were conducted via GROMACS to determine the best conformationally dynamic molecule that represents the candidate agent for the study. Following rigorous evaluation, Adozelesin, Fiduxosin, and Rimegepant have been singled out based on considerations encompassing bioavailability scores, compliance with filter criteria, and acute oral toxicity levels. Additionally, ligand interaction analysis indicates that Adozelesin and Fiduxosin exhibit an augmented propensity for hydrogen bond formation, a factor recognized for its facilitative role in protein–ligand interactions. After final analyses, we report that Fiduxosin may offer a treatment possibility by reversing the low survival rates caused by PSMB8 high activation in AML. This study represents a strategic attempt to repurpose readily available pharmaceutical agents, potentially obviating the need for de novo drug development, and thereby offering promising avenues for therapeutic intervention in specific diseases.
- Open Access
- 5 June 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (10) , 4121-4134
Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities
Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by aberrant proliferation and accumulation of lymphoid precursor cells within the bone marrow. The tyrosine kinase inhibitor (TKI), imatinib mesylate, has played a significant role in the treatment of Philadelphia chromosome-positive ALL (Ph + ALL). However, the achievement of durable and sustained therapeutic success remains a challenge due to the development of TKI resistance during the clinical course.The primary objective of this investigation is to propose a novel and efficacious treatment approach through drug repositioning, targeting ALL and its Ph + subtype by identifying and addressing differentially expressed genes (DEGs). This study involves a comprehensive analysis of transcriptome datasets pertaining to ALL and Ph + ALL in order to identify DEGs associated with the progression of these diseases to identify possible repurposable drugs that target identified hub proteins.The outcomes of this research have unveiled 698 disease-related DEGs for ALL and 100 for Ph + ALL. Furthermore, a subset of drugs, specifically glipizide for Ph + ALL, and maytansine and isoprenaline for ALL, have been identified as potential candidates for therapeutic intervention. Subsequently, cytotoxicity assessments were performed to confirm the in vitro cytotoxic effects of these selected drugs on both ALL and Ph + ALL cell lines.In conclusion, this study offers a promising avenue for the management of ALL and Ph + ALL through drug repurposed drugs. Further investigations are necessary to elucidate the mechanisms underlying cell death, and clinical trials are recommended to validate the promising results obtained through drug repositioning strategies.
- 5 June 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (10) , 4121-4134
Open AccessIntegrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities
Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by aberrant proliferation and accumulation of lymphoid precursor cells within the bone marrow. The tyrosine kinase inhibitor (TKI), imatinib mesylate, has played a significant role in the treatment of Philadelphia chromosome-positive ALL (Ph + ALL). However, the achievement of durable and sustained therapeutic success remains a challenge due to the development of TKI resistance during the clinical course.The primary objective of this investigation is to propose a novel and efficacious treatment approach through drug repositioning, targeting ALL and its Ph + subtype by identifying and addressing differentially expressed genes (DEGs). This study involves a comprehensive analysis of transcriptome datasets pertaining to ALL and Ph + ALL in order to identify DEGs associated with the progression of these diseases to identify possible repurposable drugs that target identified hub proteins.The outcomes of this research have unveiled 698 disease-related DEGs for ALL and 100 for Ph + ALL. Furthermore, a subset of drugs, specifically glipizide for Ph + ALL, and maytansine and isoprenaline for ALL, have been identified as potential candidates for therapeutic intervention. Subsequently, cytotoxicity assessments were performed to confirm the in vitro cytotoxic effects of these selected drugs on both ALL and Ph + ALL cell lines.In conclusion, this study offers a promising avenue for the management of ALL and Ph + ALL through drug repurposed drugs. Further investigations are necessary to elucidate the mechanisms underlying cell death, and clinical trials are recommended to validate the promising results obtained through drug repositioning strategies.